Stocks
GlaxoSmithKline (GSK) EBITDA margin US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 30.0% | 29.3% | 30.0% | 31.0% | 29.9% | 24.8% | ||
| Changes by years, y/y, % | +7pp | -1pp | +1pp | +1pp | -1pp | +4.6% | |||
GlaxoSmithKline. EBITDA margin, %
GlaxoSmithKline. EBITDA margin, changes, pp
GlaxoSmithKline (GSK) EBITDA margin US GAAP (quarter values) |
||||||||
| 2024Q1 | 2024Q2 | 2024Q2 | 2024Q3 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | 38.0% | 36.2% | 33.3% | 14.6% | 14.6% | 24.8% | |
| Changes by years, y/y, % | -2pp | 0pp | -3pp | -24pp | -24pp | |||
| Changes by quarters, q/q, % | +10pp | -2pp | -3pp | -19pp | 0pp | |||
